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CASE REPORT Open Access
Current antibody-based immunoassay algorithm
failed to confirm three late-stage AIDS cases in
China: case report
Yan Li1,2, Jin-Kou Zhao3, Ming Wang1, Zhi-Gang Han1, Wei-Ping Cai4, Bo-Jian Zheng5, Hui-Fang Xu1*
Abstract
Background: Immunoassays composed of screening and confirmation are the established algorithm to confirm
HIV infection in China, with a Western blot result as the final diagnosis.
Case presentation: In this report, three late-stage AIDS patients were initially tested HIV antibody positive using
multiple screening kits, but tested indeterminate using Western blot. HIV infection diagnosis was confirmed based
on nucleic acid assays, clinic manifestations and epidemiological history. Case A was identified positive at 30
months, using Western blot, Case B at 8 months, and case C remained indeterminate until he died of Kaposi’s
sarcoma 4 months after HAART.
Conclusion: The report indicates that current antibody-based testing algorithms may miss late-stage AIDS patients
and therefore miss the opportunity for preventing these cases from further transmission. The report also implies
that viral load assays is not easy to be universely applicated in developing country like China although it is helpful
in diagnosing complicated cases of HIV infection, so the counselling before and after testing is imperative to the
diagnosis of HIV infection and risk behavior survey on the examinee should be as detailed as possible.
Background
For the diagnosis of HIV infection in China, most diag-
nostic laboratories use enzyme-linked immunosorbent
assay (ELISA) tests for HIV antibody screening; further
detection of a positive screened sample is usually carried
out by using Western blot, which confirms the presence
of anti-HIV antibodies[1]. Usually, the high sensitivity
and specificity of currently used licensed screening and
confirmation reagents can ensure satisfactory results,
including relatively low frequency of false-negative and
false-positive results. However, in some instances, cases
cannot be diagnosed accurately and in a timely manner
if only the antibody was tested, such as during the sero-
conversion “window period”, the lack of specific
humoral immune response in late-stage AIDS resulting
from impaired antibody production, the infection of dis-
tinct HIV variants, etc[2,3]. Here we report three late-
stage AIDS patients, who were identified as positive on
screening tests, but persistently indeterminate on the
Western blot assays. The final diagnosis of HIV infec-
tion was based on viral load assay, clinical manifestation,
and epidemiological information.
Case presentation
Case A
A 33-year-old housewife was hospitalized in several dif-
ferent hospitals from March to June in 2005 for the fol-
lowing symptoms: persistent diarrhea, wasting, serious
throat aches, difficulty in deglutition, coughing. The phy-
sical examination identified cervical fungal infection, oral
ulcers, and oral candidiasis. Chest X-ray detected bilat-
eral pulmonary lobular pneumonia. In her self-descrip-
tion, there was no history of drug abuse, premarital sex
or extramural risk sex behavior, history of commercial
blood or plasma collection, operation history and transfu-
sion of blood/blood products. Condoms were never used
in her marriage. When her husband was diagnosed with
AIDS in June 2005, she accepted an HIV antibody test,
with two rapid test (PA) positive reactions and one third-
generation ELISA negative reaction, but an HIV-1 Wes-
tern blot indeterminate result(p24, Figure 1). At the same
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time, the CD4 cell count was only 17/μL (Supplementary
table 1). After half a year of therapy using antibiotics and
anti-epiphyte, the aforementioned symptoms were not
alleviated, and the patient was transferred to another hos-
pital in January 2006. In the latter hospital, she was tested
for HIV again, with results indicating negative status on
screening tests and an indeterminate result on the Wes-
tern blot (p24, Figure 1). AncillarDiagnostic examinations
found the following results: 106 copies/mL HIV viral
load; 7/μL CD4 cell; CRF01_AE HIV sub-type; normal
liver function; “++” urine WBC; negative results for cyto-
megalovirus (CMV), herpes, HBV, HCV, and syphilis
(Supplementary table 1). After informed consent, the
patient initiated HAART in February 2006, with the
regime being “Stocrin+Stavudine+Lamivudine” The
patient was followed up for 30 months after HAART
medication, with results indicating that not only did the
viral load decrease to lower than the detectable limit; but
CD4 cell count gradually increased and reached 323/μL,
the HIV antibody re-emerged in June 2008 and WB
tested positive (gp160 gp120p24p17, Supplementary table
1). The clinical conditions of the patient also improved
greatly, as illustrated by Supplementary table 1.
Case B
In January 2009, a 50-year-old female was hospitalized
for “a mass in the cervical anterior and a fever that
lasted for 17 days.” The admission diagnosis was AIDS
(C3), oral candidiasis, disseminated penicilliosis, and
chronic superficial gastritis. The patient initiated
HAART in January 2009, with the regime being “Stavu-
dine+ Lamivudine+Nevirapine” and she was discharged
from the hospital after 48 days. During the hospitaliza-
tion period, HIV antibody examinations indicated strong
positives on two third-generation ELISAs (Supplemen-
tary table 1), indeterminate on Western blot (gp160
gp120, Figure 1); and CD4 cell count was only 4/μL. In
March 2009, she was hospitalized again for “particles
trapped in the eyes, dim eyesight and blurred vision for
two weeks.” She stayed in the hospital for 35 days and
the diagnosis at time of discharge was AIDS (C3) com-
bined with a CMV infection. A diagnostic examination
found the following results 5 × 103 copies/mL HIV viral
load; 11/μL CD4 cell count; CRF01_AE HIV sub-type;
positive anti-HBs; 6.42 × 105 copies/mLHCMV-DNA;
Chest X-ray detected bilateral pneumonia; floaters eyes;
and negative results for herpes, HCV, and syphilis. After
Figure 1 A: Western blot results for Case A. Strip 26: positive control; strip 24: p24 (January 19, 2006); strip 14: gp160p24p17 (May 18, 2006);
strip 10: gp160p24p17 (December 7, 2006); strip17: gp160 gp120p24p17 (June 5, 2008). B: Western blot results for Case B. Strip 20: positive
control; strip 26: gp160 gp120 (January 8, 2009); strip 11: gp160 gp120 gp41 (January 22, 2009); strip 27:gp160 (March 30, 2009); strip 27: gp160
(April 30, 2009); strip 25:gp160 gp120 (May 27, 2009); strip 26: gp160 gp120p24 (August17, 2009), the brand was very weak, but allowing the
confirmation of HIV infection. C: Western blot results for Case C. Strip 26: positive control; strip 28: gp160p24 (may 7, 2009); strip36:gp160
gp120 (August 13, 2009)
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8 months of follow-up, the HIV antibody re-emerged in
August 2009 and the WB tested positive result (gp160
gp120p24, Figure 1), along with a CD4 cell count
increased from 4/μL to 63/μL.
Case C
In October of 2008, a 37-year-old man sought medical
care for “herpes in the neck”. Laboratory results showed
that cerebrospinal fluid tested positive for specific IgM
antibodies of the herpes simplex viruses, both types1 and
2 (HSV I/II). The patient was discharged from the hospi-
tal after symptoms being alleviated. In May 2009, he was
hospitalized again for “a rash covering his whole body,
continuous fever, coughing, difficulty breathing, and
symptoms similar to those of leukoplakia”. Further epide-
miologic investigation of the patient’s sexual history dis-
closed evidence of premarital sex or extramural risk sex
behavior since 2005, with about 50 female and 15 male
sex partners, and condoms were seldom used while enga-
ging in sexual activity. HIV antibodies examination indi-
cated strong positives on two third-generation ELISAs
and indeterminate on the Western blot (gp160p24, Fig-
ure 1). A diagnostic examination found the following
results: 106 copies/mL HIV viral load; 35/μL CD4 cell
count; CRF01_AE HIV sub-type; positive results for
herpes as well as with Kaposi’s sarcoma; negative results
for HBV, HCV, and syphilis. After informed consent, the
patient initiated HAART in May 2009, with a regime
being “Kaletra+Stavudine+Lamivudine”. Follow-up with
the patient continued for 4 months from the commence-
ment of HAART, neither positive HIV antibody nor
increase in CD4 cells was found (Supplementary table 1).
He died of Kaposi’s sarcoma on September 28, 2009.
Discussion
In this report, complementary and clinical examinations
detected low CD4 levels, high viral loads, and two or
more kinds of opportunistic infection in all three patients
though they were persistently indeterminate on the Wes-
tern blot assays. The discordant clinical and serological
results suggest that there may be an immunological defi-
ciency that prevents the formation of HIV-1 specific anti-
bodies. For cases A and B, CD4 cell count and antibodies
gradually increased after HAART, and HIV antibody
level was high enough to meet positive test criteria at the
end of follow-up. The most plausible explanation is that
specific HIV antibodies may have been lost in the end-
stage of AIDS and were not sufficient in meeting positive
test criteria; the re-emerging of specific antibodies at the
end of follow-up may have resulted from the reestablish-
ment of immunity by HAART. For case C, the patient
died of Kaposi’s sarcoma 4 months after HAART for the
failure of reestablishment of immunity.
Apart from the usual low level antibody, the false nega-
tive of a diagnosis of HIV infection may also be due to
some patients being infected with a very rare or unusual
strain of HIV (e.g., HIV-2, or HIV-1 group O)[4]. How-
ever, the further testing confirmed that all of the three
patients were infected by HIV-1 subtype CRF01_AE.
This is in keeping with the local epidemiology of HIV-1
of Guangzhou, where the vast majority of newly diag-
nosed HIV infections are known to be HIV subtypes BC
(51.10%), CRF01_AE (36.9%), and B (10.5%), C (5.3%) [5].
Western blot assays using whole viral lysate antigens
have been traditionally considered the “gold standard”
for confirming HIV infection[6]. However, several earlier
studies have demonstrated the unreliability of this parti-
cular assay [7-9]. In the three aforementioned cases, the
majority of samples collected during the follow-up peri-
ods indicated positive results after screening tests, alle-
ging that HIV antibodies were present; yet, after using
the Western blot assay to confirm HIV status, results
came out as indeterminate in each of the three cases.
However, the Joint United Nations Programme on HIV/
AIDS and World Health Organization has recommend
three testing strategies involving the use of one to three
enzyme-linked immunosorbent assays (ELISA) and/or
simple/rapid assays for alternative HIV confirmation.
This report is in line with the previous studies [10-12]
showed that the alternative strategies may function as
well as even better than the current algorithm (ELISA/
Western blot) with improved sensitivity, more flexibility
and lower cost. Furthermore, there was a lower fre-
quency of discordant or indeterminate results that
require follow-up testing, and the accurate diagnosis not
only allows patients who need HAART to timely treat-
ment, but also can prevent second-generation
transmission.
Moreover, although many studies [13-15] including
this report have showed that viral load detection is help-
ful in the detection and diagnosis of HIV infection,
especially when diagnosing complicated and difficult
cases of HIV infection, it is not easy to be universely
applicated in developing country like China, as the cost
is relatively high, and requisite equipment and a proper
working environment may be difficult to attain in some
instances. So this report also support that the counsel-
ling before and after testing is imperative to the diagno-
sis of HIV infection and risk behavior survey on the
eaxminee should be as detailed as possible, the final
diagnosis must be based on the laboratory testing results
and epidemiological information.
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
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consent is available for review by the Editor-in-Chief of
this journal.
Additional file 1: Results of variable testing for the three cases
during the following-up period. The data provided represent the
results of variable testing for the three cases during the following-up
period
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